Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2
Caitlin M. Rodriguez, Sophia C. Bechek, Graham L. Jones, Lisa Nakayama, Tetsuya Akiyama, Garam Kım, David E. Solow-Cordero, Stephen M. Strittmatter, Aaron D. Gitler
This study identifies RTN4R as a regulator of ataxin-2 levels and shows its potential as a therapeutic target for ALS and SCA2.
Cell Reports · Oct 1, 2022Peer-reviewedNeuroscience